TW200633720A - Medicinal composition for diabetic - Google Patents
Medicinal composition for diabeticInfo
- Publication number
- TW200633720A TW200633720A TW094143827A TW94143827A TW200633720A TW 200633720 A TW200633720 A TW 200633720A TW 094143827 A TW094143827 A TW 094143827A TW 94143827 A TW94143827 A TW 94143827A TW 200633720 A TW200633720 A TW 200633720A
- Authority
- TW
- Taiwan
- Prior art keywords
- diabetic
- medicinal composition
- inhibit
- effort
- side effects
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 abstract 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 abstract 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 abstract 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 abstract 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004359587 | 2004-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200633720A true TW200633720A (en) | 2006-10-01 |
Family
ID=36587799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094143827A TW200633720A (en) | 2004-12-13 | 2005-12-12 | Medicinal composition for diabetic |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070259928A1 (zh) |
EP (1) | EP1857118A1 (zh) |
KR (1) | KR20070086007A (zh) |
CN (1) | CN101119748A (zh) |
BR (1) | BRPI0519006A2 (zh) |
CA (1) | CA2590883A1 (zh) |
TW (1) | TW200633720A (zh) |
WO (1) | WO2006064744A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス |
KR101871011B1 (ko) * | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
WO2000014095A1 (en) * | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
WO2001047935A2 (en) * | 1999-12-22 | 2001-07-05 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
IL151248A0 (en) * | 2000-03-08 | 2003-04-10 | Metabasis Therapeutics Inc | Novel aryl fructose-1,6-bisphosphatase inhibitors |
US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
PL365779A1 (en) * | 2000-07-06 | 2005-01-10 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
US6790459B1 (en) * | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
EP1723948A1 (en) * | 2000-11-03 | 2006-11-22 | Andrx Labs, LLC | Controlled release compositions of biguanide with less side effects and treatment regimen thereof |
US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
AU2003252676A1 (en) * | 2002-07-23 | 2004-02-09 | Sankyo Company, Limited | Preventive for the onset of diabetes |
-
2005
- 2005-12-12 CN CNA2005800479814A patent/CN101119748A/zh active Pending
- 2005-12-12 BR BRPI0519006-1A patent/BRPI0519006A2/pt not_active IP Right Cessation
- 2005-12-12 CA CA002590883A patent/CA2590883A1/en not_active Abandoned
- 2005-12-12 EP EP05814764A patent/EP1857118A1/en not_active Withdrawn
- 2005-12-12 TW TW094143827A patent/TW200633720A/zh unknown
- 2005-12-12 KR KR1020077013097A patent/KR20070086007A/ko not_active Application Discontinuation
- 2005-12-12 WO PCT/JP2005/022739 patent/WO2006064744A1/ja active Application Filing
- 2005-12-12 US US11/792,879 patent/US20070259928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1857118A1 (en) | 2007-11-21 |
CN101119748A (zh) | 2008-02-06 |
KR20070086007A (ko) | 2007-08-27 |
CA2590883A1 (en) | 2006-06-22 |
BRPI0519006A2 (pt) | 2008-12-23 |
WO2006064744A1 (ja) | 2006-06-22 |
US20070259928A1 (en) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2011000176A1 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
IL179515A0 (en) | Method of administering and using vegf inhibitors for the treatment of human cancer | |
GB2431346C (en) | A combination composition comprising paracetamol and ibuprofen | |
MX2009006007A (es) | Profarmacos y metodos para hacer y usar los mismos. | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
HK1091127A1 (en) | Compounds and methods for downregulating the effects of tgf-beta | |
IL175014A0 (en) | Method of administering therapeutic injections | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
WO2007149782A3 (en) | Selective inhibitors for transferases | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
TW200633720A (en) | Medicinal composition for diabetic | |
MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
UA88655C2 (ru) | S-миртазапин для лечения прилива крови | |
EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
MXPA03001227A (es) | Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. | |
WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
TW200633702A (en) | Medicinal composition containing fbpase inhibitor | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
WO2006042277A3 (en) | Extended release compositions of proton pump inhibitors | |
TW200738245A (en) | Pharmaceutical composition containing FBPase inhibitor | |
TW200738266A (en) | Pharmaceutical agent containing insulin resistance improving agent |